NewYork-Presbyterian Hospital

NewYork-Presbyterian Hospital, based in New York City, is one of the nation’s largest and most comprehensive hospitals and a leading provider of inpatient, ambulatory and preventive care in all areas of medicine. With some 2,600 beds and more than 6,700 affiliated physicians and almost 22,000 employees, NewYork-Presbyterian had more than 2 million visits in 2014, including some 14,000 infant deliveries and more than 262,000 emergency department visits. NewYork-Presbyterian comprises six campuses: NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children’s Hospital, NewYork-Presbyterian/The Allen Hospital, NewYork-Presbyterian/Westchester Division and NewYork-Presbyterian/Lower Manhattan Hospital. The hospital is also closely affiliated with NewYork-Presbyterian/Hudson Valley Hospital, NewYork-Presbyterian/Lawrence Hospital and NewYork-Presbyterian/Queens. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area, and # 7 in the nation according to U.S. News & World Report, and consistently named to the magazine’s Honor Roll of best hospitals in the nation. Affiliated with two world-renowned medical schools, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, NewYork-Presbyterian is committed to excellence in patient care, research, education and community.

For more information, visit www.nyp.org.

NewYork-Presbyterian/ Morgan Stanley Children’s Hospital

For nine years running, NewYork-Presbyterian Morgan Stanley Children’s Hospital (NYPMSCH) ranks in more pediatric specialties than any other New York metro area hospital in U.S. News & World Report’s “Best Children’s Hospitals.” NewYork-Presbyterian Morgan Stanley Children’s Hospital ranks among the top in the nation for children’s care in every specialty evaluated in the U.S. News survey, which includes cancer, cardiology and heart surgery, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology. NewYork-Presbyterian/Morgan Stanley Children’s Hospital, which is affiliated with Columbia University Medical Center and the College of Physicians and Surgeons, has built a reputation for more than a century as one of the nation’s premier centers for pediatric care. Together, they offer the best available care in every area of pediatrics including the most complex neonatal and critical care, and all areas of pediatric surgery in a family-friendly and technologically advanced setting. They are also major international referral centers, meeting the special needs of children from infancy through adolescence worldwide. U.S. News & World Report.

The facilities of the NYPMSCH include the new patient tower as well as the central and north buildings. The hospital has 250 beds of which 50 % are intensive care including neonatal and pediatric critical care units. There is a recently opened pediatric and adolescent neurology and neurosurgery ICU that is the first of its kind in the tri-state region. Dedicated in-patient floors exist for oncology and stem cell transplant, cardiology, neurology and general medicine and surgery. The CMI an indication of patient acuity is one of the highest in the United States. The residents and fellows at NYPMSCH are among the best and the brightest and the nursing staff is dedicated, compassionate and the patient to nurse ratio is very favorable.

For more information, visit www.childrensnyp.org.

Columbia Children’s Health

Columbia Children’s Health (CCH) is the academic designation of the faculty of the College of Physicians and Surgeons of Columbia University and the Columbia University Medical Center. The entity unites the best and the brightest minds to conduct critical research and inspired care. Our dedicated doctors, surgeons and researchers are experts in 33 specialty areas and our programs are nationally ranked in nine of ten specialties and considered among the strongest programs in the country.

The physicians and scientists of Columbia Children’s Health have a long tradition of innovation and developing advanced therapies that help cure diseases of children. For more than 125 years we have been at the forefront of significant breakthroughs in pediatric medicine; our doctors were the first to describe cystic fibrosis, the development of the APGAR score for newborns, the treatment of Rh hemolytic disease of neonates, and the first pediatric heart transplant. Building on this extraordinary history the faculty of Columbia University Children’s Health continue to provide care inspired science.

Columbia Children’s Health, working in concert with our hospital partner, New York Presbyterian Morgan Stanley Children’s Hospital (NYP-MSCH), is an extraordinary environment for the care of complex diseases in children and adolescents. Together with the NYP-MSCH the services we provide range from prenatal management and newborn treatments to the transition of care for young adults with chronic illness to adult services. We are dedicated to not only the patients and families of the New York metropolitan region, but our groundbreaking discoveries help patients and families from all over the world. We offer care for common issues of childhood to the most complex and intensive services including diseases of the brain, heart, cancer.

The goals of Columbia Children’s Health:

  • Provide compassionate medical, surgical and behavioral care
  • Disseminate knowledge locally and globally
  • Conduct innovative care inspired science
  • Retain, recruit outstanding clinicians and scientists
  • Educate the best and the brightest to lead for tomorrow
  • Perpetuate our historic legacy

At Columbia Children’s Health every family can be confident that they have a team of world-class experts behind them and a trusted clinician at their side. You will find our doctors and nurses to be laser focused on medicine. We are: INTELLIGENT, APPROACHABLE, PASSIONATE, and BOLD.

Herbert Irving Comprehensive Cancer Center

The Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University (CU) is the University’s organizational structure for the conduct of basic, clinical and population-based cancer research and patient care. Initially funded by the National Cancer Institute (NCI) in 1972 and designated comprehensive in 1979, the HICCC is one of only 41 NCI-designated comprehensive cancer centers in the United States, of which only three are in New York State.. The Research Programs of the HICCC are organized into three sections: basic, disease specific and population-based programs as well as 15 shared resources. Program activities focus on different aspects of cancer, from its molecular and cellular mechanisms through its unique behavior in different tissues to statistical aspects of its occurrence and treatment in large populations. Today the HICCC has more than 200 members including the pediatric oncology and stem cell transplant faculty who are engaged in basic, translational and clinical research enterprises. The members of each program share a commitment to reduce cancer incidence and tumor progression and to improve the quality of life of those affected by cancer.

Researchers and physician scientists at the HICCC scientists are dedicated to understanding the biology of cancer and using that knowledge to develop more effective cancer therapies and prevention strategies. Clinical trials are an essential part of that process. A clinical trial is a type of research study conducted to discover new and better ways to prevent, diagnose and treat diseases. Nearly all cancer treatments used today were studied and first made available to patients through clinical trials. Child and adolescent patients cared for at Columbia Doctors Children’s Health Division are eligible to participate in clinical trials under the auspices of the Children’s Oncology Group, Dana Farber Cancer Institute, NANT (New Advances in Neuroblastoma Treatment) and TACL (Therapeutic Advances in Childhood Leukemia. A trial follows the progress of a disease and may span many years. Throughout this time, every trial is carefully monitored to assure each patient’s privacy and protection.

For more information, visit www.hiccc.columbia.edu